Regulatory alerts
Drug Safety Update: erythromycin
MHRA says caution is required due to cardiac risks (QT interval prolongation) and warns of a potential drug interaction with rivaroxaban.
Drug Safety Update: erythromycin in children
MHRA issues update on known risk of infantile hypertrophic pyloric stenosis.
Drug Safety Update: Systemic and inhaled fluoroquinolones
Small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk.